Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.04 (overall 0.09) | 0.04 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in retinal ganglion cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 78 | 0.70 |
| pathways Reactome | 6 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 2859
Sealed predictions
- CPLX1 in dopamine neurons, braak-0.17 (p 0.665) → +0.14 (p 0.725)receipt 2866
In the sealed studies
- The synaptic vesicle cycle in resilient donors: did not hold
Swarm cases
receipt 2866: CPLX1 in dopamine neurons, braak
- power
- full sample +0.04 (p 0.874, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.874, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.840, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.16, sign flips 4; without severely affected donors +0.04 (p 0.874, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CPLX1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts